Cellular Therapies Leading to New Treatment Options for Lymphoma Patients - Takeaways - MDSpire

Cellular Therapies Leading to New Treatment Options for Lymphoma Patients

A new CAR T-cell consortium, Matthew Cortese, MD, MPH, a hematologic oncologist at Roswell Park Comprehensive Cancer Center, shares that certain types of hard-to-treat lymphomas may be more receptive to immunotherapies than previously thought.

  • June 30, 2025

Share

  • 1

    Certain hard-to-treat lymphomas show high receptivity to immunotherapies, including CAR T-cell therapy.

  • 2

    Venetoclax has successfully improved outcomes for patients with hyper-progressive lymphoma, allowing for extended survival.

  • 3

    Dr. Cortese's team is developing trials to enhance treatment efficacy while reducing toxicity in lymphoma patients.

  • 4

    Research into complement biology has shown promising results in ovarian cancer, aiming to improve patient outcomes.

  • 5

    Roswell Park Comprehensive Cancer Center is pioneering novel cell therapies and collaborating on national standards of care.

Original Source(s)

Cellular Therapies Leading to New Treatment Options for Lymphoma Patients

  • June 30, 2025

Related Content

FOXA2 in cancer: from fundamental biology to clinical translation

Diffuse large B-cell lymphoma presenting as a scalp tumor with skull destruction and neurological symptoms: a case report

Stimuli-responsive nanoplatforms for sonodynamic immunotherapy: opportunities and challenges in cancer treatment